RNS Number : 8536E
Kromek Group PLC
27 October 2025

27 October 2025

Kromek Group plc
("Kromek" or the "Group")

Pre-close Trading Statement

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, provides the following update on trading for the six months ending 31 October 2025 ("H1 2026").

The Group expects to report revenue for H1 2026 of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.

As a result of the increase in revenue, along with an expected improvement in gross margin due to the contribution from Siemens Healthineers, the Group expects to report profit before tax and positive adjusted EBITDA for the first half of 2026 compared with a loss before tax of £5.7m and an adjusted EBITDA loss of £2.3m for H1 2025.

The Group's trading for the first half of the year reinforces the Board's confidence that the Group will deliver revenue growth for FY 2026 with results in line with market expectations

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance — +44 (0)20 7220 0500
Tim Redfern - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTFEMEFMEISEDS